Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Axcella Health Inc.
  6. Summary
    AXLA   US05454B1052

AXCELLA HEALTH INC.

(AXLA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/20/2021 07/21/2021 07/22/2021 07/23/2021 07/26/2021 Date
3.54(c) 3.83(c) 3.67(c) 3.57(c) 3.46(c) Last
116 448 126 067 60 393 58 410 92 338 Volume
+1.14% +8.19% -4.18% -2.72% -3.08% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -68,7 M - -
Net cash position 2021 15,6 M - -
P/E ratio 2021 -1,96x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -82,2 M - -
Net Debt 2022 3,04 M - -
P/E ratio 2022 -1,61x
Yield 2022 -
Capitalization 131 M 131 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 59
Free-Float 76,4%
More Financials
Company
Axcella Health Inc. is a biotechnology company. The Company focuses on research and development of multifactorial interventions to support health and address dysregulated metabolism across a spectrum of consumers. It designs and develops endogenous metabolic modulators. Its AXA Development Platform produces a pipeline of AXA candidates with programs in liver, muscle and blood. The Company’s wholly owned pipeline... 
Read more
More about the company
Ratings of Axcella Health Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
D+
More Ratings
All news about AXCELLA HEALTH INC.
07/22AXCELLA : to Report Second Quarter 2021 Financial Results on July 29, 2021
BU
07/06SECTOR UPDATE : Health Care Stocks Sit Out Recovery As Biotechs Weigh
MT
07/06SECTOR UPDATE : Health Care Stocks Under the Weather
MT
07/06Wall Street Set for Flat Open as Traders Return from Long Holiday Weekend
MT
07/06AXCELLA HEALTH : HC Wainwright Starts Axcella Health at Buy With $14 Price Targe..
MT
06/30AXCELLA HEALTH : Starts Phase 2 Trial of Treatment for Recurrent Overt Hepatic E..
MT
06/30AXCELLA : Announces Initiation of EMMPOWER℠ Phase 2 Clinical Trial of AXA1..
BU
06/30Axcella Announces Initiation of EMMPOWER Phase 2 Clinical Trial of AXA1665
CI
06/25AXCELLA HEALTH INC.(NASDAQGM : AXLA) dropped from Russell 3000E Value Index
CI
06/25AXCELLA HEALTH INC.(NASDAQGM : AXLA) dropped from Russell 2500 Growth Index
CI
06/25AXCELLA HEALTH INC.(NASDAQGM : AXLA) dropped from Russell 3000E Index
CI
06/25AXCELLA HEALTH INC.(NASDAQGM : AXLA) dropped from Russell 2000 Index
CI
06/25AXCELLA HEALTH INC.(NASDAQGM : AXLA) dropped from Russell Small Cap Comp Growth ..
CI
06/25AXCELLA HEALTH INC.(NASDAQGM : AXLA) dropped from Russell 3000 Value Index
CI
06/25AXCELLA HEALTH INC.(NASDAQGM : AXLA) dropped from Russell 2500 Index
CI
More news
News in other languages on AXCELLA HEALTH INC.

- No features available -

More news
Analyst Recommendations on AXCELLA HEALTH INC.
More recommendations
Chart AXCELLA HEALTH INC.
Duration : Period :
Axcella Health Inc. Technical Analysis Chart | AXLA | US05454B1052 | MarketScreener
Technical analysis trends AXCELLA HEALTH INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 3,46 $
Average target price 14,88 $
Spread / Average Target 330%
EPS Revisions
Managers and Directors
William R. Hinshaw President, Chief Executive Officer & Director
Laurent Chardonnet Chief Financial Officer & Senior Vice President
David R. Epstein Chairman
Tony Tramontin Chief Scientific Officer, Senior VP-R&D
Alison Schecter President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
AXCELLA HEALTH INC.-33.33%131
GILEAD SCIENCES, INC.18.01%86 563
BIONTECH SE251.15%69 138
WUXI APPTEC CO., LTD.32.49%67 035
REGENERON PHARMACEUTICALS19.60%59 833
VERTEX PHARMACEUTICALS-15.83%51 496